Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company PharmaMar S.A.
DescriptionMarine-derived tubulin inhibitor covalently bound to trastuzumab with a non-hydrolysable linker
Molecular Target Tubulin
Mechanism of ActionAntibody-drug conjugate; Tubulin inhibitor
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today